

Medicines and Healthcare products Regulatory Agency

CERTIFICATE NUMBER : UK MIA(IMP) 17328 Insp IMP 17328/23930512-0005[I]

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER(1),(2)

Part 1

Issued following an inspection in accordance with :

Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

The competent authority of United Kingdom confirms the following :

The Manufacturer : ZAYED CENTRE FOR RESEARCH INTO RARE DISEASE IN CHILDREN

Site address : ZAYED CENTRE FOR RESEARCH INTO RARE DISEASE IN CHILDREN, 20 GUILFORD STREET, LONDON, WC1N 1DZ, UNITED KINGDOM

Has been inspected under the national inspection programme in connection with manufacturing authorisation no. UK MIA(IMP) 17328 in accordance with Part 6 of The Medicines for Human Use (Clinical Trials) Regulations 2004 (SI 2004/1031)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on 24/05/2023 , it is considered that it complies with

- The principles and guidelines of Good Manufacturing Practice laid down in Regulation B17 of the Human Medicines Regulations 2012 (as amended)

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in MHRA-GMDP. If it does not appear, please contact the issuing authority.

- (1) Guidance on the interpretation of this template can be found in the Help menu of MHRA-GMDP database.
- (2) These requirements fulfil the GMP recommendations of WHO.

Part 2

Human Investigational Medicinal Products

1. MANUFACTURING OPERATIONS

[1.1] Sterile Investigational Medicinal Products

[1.1.1] Aseptically prepared (processing operations for the following dosage forms)

[1.1.1.4] Small volume liquids

[1.1.3] Batch certification

[1.3] Biological investigational medicinal products

[1.3.1] Biological medicinal products

[1.3.1.3] Cell therapy products

[1.3.1.4] Gene therapy products

Viral vectors

[1.3.2] Batch certification

[1.3.2.3] Cell therapy products

[1.3.2.4] Gene therapy products

Viral vectors

[1.4] Other products or manufacturing activity

[1.4.2] Sterilisation of active substances/excipients/finished products:

[1.4.2.1] Filtration

[1.5] Packaging

[1.5.2] Secondary packaging

2. IMPORTATION OF MEDICINAL PRODUCTS

[2.3] Other Importation Activities

[2.3.2] Importation of Intermediate which undergoes further processing

[2.3.4] Other

Importation of QP-certified IMPs from a country on the approved country for import list

Restrictions or Remarks

GOSH ZCR operations restricted to Grade C rooms with isolator or closed manufacture

IMP importation activities restricted to supplies directly into the licenced GOSH facility(not supply to other facilities or 3rd party sites)

| | |
|------------|---|
| 15/10/2023 | Name and signature of the authorised person of the Competent Authority of United Kingdom Confidential Medicines and Healthcare products Regulatory Agency Tel : Confidential |
|------------|---|